An interventional study of Epidural and Rectus Sheath Catheters in Bladder Cancer and Postoperative Pain, sponsored by Vancouver Coastal Health. Status unknown at 1 site in Canada. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2016-11-02.
Sponsored by Vancouver Coastal Health · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 153 studies in Urinary Bladder Neoplasms with a site in Canada — 32 open to participants now, 59 under way, 21 of them phase 3. Urinary Bladder Neoplasms · Canada.
Among the 153 studies in Urinary Bladder Neoplasms with a site in Canada, this one is the 64th largest by planned enrollment of the 135 interventional ones that give a count, is one of 9 that started in 2015, is one of 13 with no phase, and was the 55th registered.
1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.
Browse Urinary Bladder Neoplasms studies →32 of the 153 studies in Urinary Bladder Neoplasms with a site in Canada are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Canada, United States, Australia and 13 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Canada, United States, Australia and 1 more country
Ages 18+
Astellas Pharma Global Development, Inc. · Sites in Canada, United States, Brazil and 3 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Canada, United States, Argentina and 14 more countries
Ages 18+
Photocure · Sites in Canada, United States, Belgium and 2 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
153 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 37 · Phase 2 65 · Phase 3 46
First in 1996; this study’s year is marked. 9 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 60 across 1,299 interventional studies indexed under Urinary Bladder Neoplasms.
Median enrollment 154 across the 135 interventional studies, 209 across the 16 observational. Of the 84 that completed or were terminated, 34 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
91 of 153 have an industry lead sponsor. The 10 most frequent:
Vancouver Coastal Health is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Vancouver Coastal Health has 2 studies filed under Urinary Bladder Neoplasms — fewer than ten, so there is no comparison to draw.
17 of the studies in Urinary Bladder Neoplasms with a site in Canada that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06111235Phase 3CG Oncology, Inc.A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | 2026-11 |
| NCT04658862Phase 3Janssen Research & Development, LLCA Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder | 2026-12-30 |
| NCT05911295Phase 3Seagen, a wholly owned subsidiary of PfizerDisitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | 2027-01-29 |
| NCT02869217University Health Network, TorontoStudy of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors | 2026-11 |
| NCT04963153National Cancer Institute (NCI)Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy | 2026-12-01 |
Add all 17 to your calendar (.ics) → With an account.
Among the 153 studies in Urinary Bladder Neoplasms with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective randomised controlled trial that will compare the outcomes of rectus sheath catheters to epidurals in patients who have undergone a cystectomy, via a lower midline abdominal incision for bladder cancer.
This study will compare the outcomes of two different pain control techniques, used as standard of care, following major abdominal surgery for bladder removal. Rectus sheath catheters are small tubes that are positioned into a specific area of the cut abdominal wall at the end of surgery; whereas an epidural is a tube that is positioned into the back. Both allow administration of local anaesthetic for pain control. The current gold standard is an epidural. This study will aim to evaluate this and show the comparative efficacy of the rectus sheath catheter, which anecdotally the investigators have found superior in practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will have rectus sheath catheters surgically inserted with infusion of 0.125% Bupivicaine at 5mls an hour.
Device: Rectus Sheath Catheters
Patients will have a standard epidural placement with infusion of 0.125% Bupivicaine at an initial rate of 5mls/hour, titrated to response
Device: Epidural
Patients in this group will have an epidural inserted in a standard fashion, prior to the induction of anesthesia. These will be infused with 0.125% Bupivicaine at an initial rate of 5mls/hour, titrated to response. Patients will also receive a patient controlled analgesia with hydromorphone 0.2mg/ml, bolus of 200 micrograms with 6 minute lock out (variable in accordance with anesthetic preference).
Patients in this group will have surgically inserted rectus sheath catheters (bilaterally), immediately prior to closure of the anterior abdominal wall. These will be infused with 0.125% Bupivicaine at 5mls an hour at a standard rate.Patients will also receive a patient controlled analgesia with hydromorphone 0.2mg/ml, bolus of 200 micrograms with 6 minute lock out (variable in accordance with anesthetic preference).
Cumulative post-operative opioid consumption
Time frame: To Day 3 post-op
Visual Analogue Score pain score
Time frame: within 4 hours post-operatively and on days 1, 2 and 3 post-operatively
Patient total intraoperative Opioid requirement
Opioid requirement will be measured in morphine equivalents and reported as such on a per patient basis and measured throughout the operation.
Time frame: Intraoperatively
Total patient fluid requirements throughout hospital admission
Measurement of individual patient fluid balance will be performed up to and including day 3 post-operatively.
Time frame: From the start of the operation to day 3 post-operatively.
Recorded evidence of hypotension
Hypotension for the purposes of this study is defined as a systolic blood pressure of less than 95.
Time frame: Until Day 3 postoperatively
Duration of post-operative ileus
Ileus will be measured by a 3 separate variables - bowel sounds, passing of flatus and opening of bowels. The post-operative day on which each of these targets is achieved for each patient will be recorded.
Time frame: This will be measured during the patients' inpatient hospital stay - usually up to a maximum of 10 days.
Time to mobilisation
Time frame: The day at which patient achieves mobilisation - usually at a maximum of 5 days post-operatively
Length of Hospital Stay
Time frame: The day at which patient is discharged from hospital- usually on average 10 days post-operatively
Patient Satisfaction with pain control
Patient satisfaction with pain control will be measured using a 9-point Likert scale on day 3 post-operatively.
Time frame: Day 3 post operatively
Complications and side effects.
At 30 days an electronic note review will be performed to evaluate for 30 day mortality and morbidity.
Time frame: 30 day morbidity and mortality
The record gives a start of Sep 2015, a primary completion of Dec 2016 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vancouver Coastal Health